市場調査レポート

商品コード

1455127

組み換えワクチンの世界市場規模、シェア、成長分析、エンドユーザー別、流通チャネル別-産業予測、2024～2031年

Global Recombinant Vaccines Market Size, Share, Growth Analysis, By End user(Pediatric and Adult), By Distribution channel(Hospitals and Vaccination centers) - Industry Forecast 2024-2031

出版日: 2024年03月17日 | 発行: SkyQuest

| ページ情報: 英文 219 Pages | 納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 832,842円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 974,268円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,115,694円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
目次

概要

サンプル依頼リストに入れる

組み換えワクチンの世界市場規模は2022年に90億2,000万米ドルと評価され、予測期間中（2024～2031年）のCAGRは11.40%で、2023年の100億5,000万米ドルから2031年には238億3,000万米ドルに成長する展望です。

過去において、初期のワクチンは弱毒化または不活性化した病原体に個人をさらす方法に大きく依存していました。しかし、遺伝子工学、ゲノミクス、組み換えDNA技術の出現により、ワクチン開発の状況は大きく変化しました。これらの革新的なアプローチにより、現在市販されている新しいワクチンが生み出されています。従来の方法とは異なり、これらのワクチンは管理された実験室で製造され、遺伝子スクリーニング技術を活用して感染症に関連するリスクを軽減しています。これはワクチンの有効性を高めるだけでなく、ワクチン接種過程における安全性にも最も重点を置いています。遺伝子工学とワクチン開発の融合は、より正確で的を絞った予防接種へのアプローチを可能にし、重要な進歩を示しています。

技術分析
価格分析
サプライチェーン分析
バリューチェーン分析
市場のエコシステム
IP分析
貿易分析
スタートアップ分析
原材料の分析
イノベーションマトリクス
パイプライン製品の分析
マクロ経済指標
主要投資の分析
主要成功要因
競合の程度

市場力学と展望

市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
規制情勢
ポーターの分析
将来の混乱についての特別な考察

組み換えワクチンの世界市場：エンドユーザー別

市場概要
小児と成人

組み換えワクチンの世界市場：流通チャネル別

市場概要
病院と予防接種センター

組み換えワクチンの世界市場規模：地域別

市場概要
北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域

競合情勢

上位5社の比較
主要企業の市場ポジショニング（2021年）
主要市場企業が採用した戦略
主要成功戦略
市場における最近の活動
主要企業の市場シェア（2021年）

主要企業プロファイル

AstraZeneca Plc.
Dynavax Technologies Corporation
Emergent BioSolutions Inc.
GlaxoSmithKline Plc.
Johnson & Johnson, Merck & Co. Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi S.A.
Serum Institute of India Pvt. Ltd.

Product Code: SQMIG35A2767

Global Recombinant Vaccines Market size was valued at USD 9.02 Billion in 2022 and is poised to grow from USD 10.05 Billion in 2023 to USD 23.83 Billion by 2031, at a CAGR of 11.40% during the forecast period (2024-2031).

In the past, early vaccines heavily relied on methods that involved exposing individuals to weakened or deactivated pathogens. However, with the emergence of genetic engineering, genomics, and recombinant DNA technologies, the landscape of vaccine development has undergone a profound transformation. These innovative approaches have led to the creation of new vaccines now available in the market. Unlike traditional methods, these vaccines are crafted in controlled laboratory environments, leveraging genetic screening techniques to mitigate the risks associated with infectious diseases. This not only enhances vaccine efficacy but also places a paramount emphasis on safety during the vaccination process. The fusion of genetic engineering and vaccine development marks a significant advancement, enabling a more precise and targeted approach to immunization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Recombinant Vaccines Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Recombinant Vaccines Market Segmental Analysis

On the basis of indication, the market is classified into human papillomavirus, meningococcal and others. On the basis of end user, the market is bifurcated into pediatric and adult. On the basis of distribution channel, the market is classified into hospitals and vaccination centers. Region wise, the market is studied across North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa.

Drivers of the Global Recombinant Vaccines Market

A key factor driving market growth is the widespread use of recombinant properties, which significantly improve the effectiveness and safety of vaccines administered to patients. The inherent advantages of this technology enable rapid and large-scale vaccine production, reducing the risk of supply shortages. Additionally, these vaccines lack infectious viral particles, making them safe for individuals with compromised immune systems. The significant benefits of recombinant vaccines have prompted manufacturers to prioritize the development of innovative products targeting viral diseases. This effort involves harnessing advanced DNA technology, genomics, and other cutting-edge biotechnological techniques, collectively contributing to the development of more effective and safer vaccines.

Restraints in the Global Recombinant Vaccines Market

Despite the increased incidence of chronic and infectious diseases, the widespread uptake of vaccines is hindered by several factors, notably the exorbitant cost per dose. Despite the diligent efforts of international organizations in distributing millions of doses worldwide, the prohibitive expense of vaccination remains a significant obstacle for numerous populations. Despite concerted endeavors to ensure global coverage, certain regions still struggle with vaccine accessibility due to the enduring issue of high costs.

Market Trends of the Global Recombinant Vaccines Market

The rising prevalence of infectious diseases globally has sparked a critical need for efficient vaccines. This necessity is heightened by the heightened vulnerability of elderly and pediatric populations to severe illnesses, emphasizing the urgent requirement for swift vaccination initiatives on a global scale. Organizations like UNICEF and PAHO have been pivotal in distributing millions of vaccine doses to nations confronting urgent requirements, bolstering efforts to halt the spread of various diseases. Their effective procurement strategies have significantly curbed disease transmission and fortified communities against these health hazards.

Executive Summary

Market Overview
Wheel of Fortune

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Parent Market Analysis

Market Overview
Market Size
Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges

Key Market Insights

Technology Analysis
Pricing Analysis
Supply Chain Analysis
Value Chain Analysis
Ecosystem of the Market
IP Analysis
Trade Analysis
Startup Analysis
Raw Material Analysis
Innovation Matrix
Pipeline Product Analysis
Macroeconomic Indicators
Top Investment Analysis
Key Success Factor
Degree of Competition

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Regulatory Landscape
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact

Global Recombinant Vaccines Market by End user

Market Overview
Pediatric and Adult

Global Recombinant Vaccines Market by Distribution channel

Market Overview
Hospitals and Vaccination centers

Global Recombinant Vaccines Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2021
Strategies Adopted by Key Market Players
Top Winning Strategies
- By Development
- By Company
- By Year
Recent Activities in the Market
Key Companies Market Share (%), 2021

Key Company Profiles

AstraZeneca Plc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline Plc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson, Merck & Co. Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Serum Institute of India Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments